Overview

The Purpose of This Study is to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo as Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Po

Status:
Not yet recruiting

Trial end date:
2028-10-31

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with previously untreated HER2-positive advanced breast cancer (ABC).

Phase:

Phase 3

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

Inavolisib
Taxane